Nucleic acid therapeutics are based on nucleic acids or closely related chemical compounds. They include antisense oligonucleotides, aptamers and small interfering RNAs, and are typically ...

The development of nucleic-acid therapeutics, ranging from aptamers and antisense RNA to messenger RNA (mRNA)-based vaccines and gene therapies, is a rapidly evolving industry that has the ...

Antisense oligonucleotide (ASO) technology has accelerated drug discovery in the ... This webinar will explore the most recent ASO chemical modification: locked nucleic acid (LNA), which confers high ...

At first, researchers thought that antisense drugs would prove so specific there would be few side effects. But toxicity-related problems did arise in initial animal studies of antisense drugs in the ...

Updated results from BP1001-A obesity and Type 2 diabetes testing from the second stage of pre-clinical testing are as follows: Previously, Bio-Path reported BP1001-A increased insulin sensitivity in ...

"Nucleic Acid Therapeutics welcomes this fine addition to the armamentarium of bioanalytical assays needed to identify ...

Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio ...

A new article in the journal Nucleic Acid Therapeutics addresses the recognition by the U.S. Food and Drug Administration that immunogenicity assays may be necessary to measure immune responses to ...